Alzheon’s Pill For Alzheimer’s Recruits for Clinical Trialsalzheon2022-11-07T18:32:37-05:00October 12th, 2022|
Alzheon Biomarker Trial Brings Insight to Stalled Treatment Spacealzheon2022-10-02T16:55:56-04:00September 20th, 2022|
Alzheimer’s Drug Developer Alzheon Secures $50 Millionalzheon2023-05-01T08:55:43-04:00April 14th, 2022|
Big Pharma Abandoned Alzheimer’s, This Good Unicorn Stayed And Found A Potential Curealzheon2021-11-09T18:42:03-05:00November 9th, 2021|
Martin Tolar of Alzheon receives the “Czech Laurels Award” from the Chamber of Commerce of the Czech Republicalzheon2021-10-20T19:25:19-04:00October 12th, 2021|
Milepost ALZ-801. Martin Tolar leads one of the greatest Czech successesalzheon2021-10-11T18:57:33-04:00September 7th, 2021|
Breaking News in the Field of Alzheimer’s: Alzheon Announces First Patient Dosed in Phase 3 Trialalzheon2021-07-08T10:38:04-04:00July 6th, 2021|